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Background: In order to improve the clinical outcome of patients with locally advanced squamous cell carcinoma of
the head and neck (LASCCHN) not being capable to receive platinum-based chemoradiation, radiotherapy can be
intensified by addition of cetuximab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR).
The radioimmunotherapy with cetuximab is a feasible treatment option showing a favourable toxicity profile. The most
frequent side effect of radiotherapy is radiation dermatitis, the most common side effect of treatment with cetuximab
is acneiform rash. Incidence and severity of these frequent, often overlapping and sometimes limiting skin reactions,
however, are not well explored. A clinical and molecular differentiation between radiogenic skin reactions and skin
reactions caused by cetuximab which may correlate with outcome, have never been described before.
Methods/design: The HICARE study is a national, multicenter, prospective phase IV study exploring the different types
of skin reactions that occur in patients with LASCCHN undergoing radioimmun(chemo)therapy with the EGFR inhibitor
cetuximab. 500 patients with LASCCHN will be enrolled in 40 participating sites in Germany. Primary endpoint is the
rate of radiation dermatitis NCI CTCAE grade 3 and 4 (v. 4.02). Radioimmunotherapy will be applied according to SmPC,
i.e. cetuximab will be administered as loading dose and then weekly during the radiotherapy. Irradiation will be applied
as intensity-modulated radiation therapy (IMRT) or 3D-dimensional radiation therapy.
Discussion: The HICARE trial is expected to be one of the largest trials ever conducted in head and neck cancer
patients. The goal of the HICARE trial is to differentiate skin reactions caused by radiation from those caused by the
monoclonal antibody cetuximab, to evaluate the incidence and severity of these skin reactions and to correlate them
with outcome parameters. Besides, the translational research program will help to identify and confirm novel peripheral
blood based molecular predictors and surrogates for treatment response and resistance.
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Squamous cell carcinomas of the oropharynx, hypophar-
ynx and larynx are the sixth leading cancer by incidence
worldwide with more than 500000 new cases a year. At
the time of diagnosis most patients display signs and
symptoms of locally advanced disease and have lymph
node metastases [1]. SCCHN is mostly caused by tobacco
and alcohol consumption and/or infection with high-risk
types of human papillomavirus (HPV) [2]. SCCHN often
show an overexpression of epidermal growth factor recep-
tors (EGFR) which is described to be associated with a
poor prognosis [3-6]. Standard treatment for resectable
tumors is surgery including reconstruction plus post-
operative radiotherapy and, for those patients found at
surgery to have high risk features (extracapsular extension
and/or R1 resection), post-operative chemoradiation with
single agent platinum [7,8]. At present, for non-resectable
patients who can tolerate it, combined concomitant
chemoradiation with platinum is the standard treatment
[9,10]. Organ-preservation protocols with combined che-
moradiation therapy and surgery for salvage are increas-
ingly being performed. These protocols are particularly
effective for young patients with a good performance
status presenting with moderately-advanced laryngeal or
pharyngeal SCC. For patients who are not capable to
receive standard platinum-based chemoradiation due to
age, generally reduced condition and/or comorbidities, e.g.
heart and renal disease or cirrhosis of the liver, the treat-
ment of choice is radioimmunotherapy with cetuximab
[7,8,11,12]. Whereas results of a standard chemoradiation
are based on thousands of patients, results of the com-
bined radioimmunotherapy are only based on about 200
patients in the experimental arm of the pivotal trial
[11,12]. A study comparing the standard platinum-based
chemoradiation with the novel radioimmunotherapy
protocol with the anti-EGFR antibody cetuximab, how-
ever, is still missing. Hence, guidelines still recommend
standard radiochemotherapy with cisplatin for patients
able to receive chemotherapy [9,10].
Cetuximab is a chimeric monoclonal IgG1 antibody spe-
cifically targeting the epidermal growth factor receptor
(EGFR). EGFR signal cascades are involved in cell prolifer-
ation, in cell cycle regulation, in angiogenesis, cell migra-
tion and invasion and in metastases. Cetuximab binds to
the EGFR in a 5 to 10 times higher affinity than endogen
ligands leading to a downregulation of EGFR molecules
on the cell surface. Intracellular phosphorylation of the
EGFR is inhibited and consequently the down stream sig-
nalling is deficient resulting in cell cycle arrest, increased
expression of pro-apoptotic enzymes and decrease in the
production of matrix metalloproteinases. Effects of EGFR
inhibition that have been described are a reduction of cell
proliferation, an inhibition of cell division processes and
tumor growth and an increase of apoptosis [13,14].Furthermore, cetuximab treatment leads to a decrease in
the production of vascular endothelial growth factor
(VEGF) blocking angiogenic processes in the tumor.
Cetuximab has been found to potentiate the effects of
radiotherapy in experimental systems [13-15].
Combined radioimmunotherapy with cetuximab is a
well accepted treatment option in patients with locally
advanced squamous cell carcinoma of the head and neck
(LASCCHN) if they are not able to receive surgery or
combined radiochemotherapy due to stage, reduced gen-
eral condition and/or comorbidities. In the pivotal, inter-
national, randomized Phase III trial of 424 patients with
locally or regionally advanced squamous cell carcinoma
of the oropharynx, hypopharynx or larynx with no prior
therapy, the addition of cetuximab to radiation when com-
pared to radiation alone resulted in a higher response rate,
a 9.5- month improvement in median duration of
locoregional control [24.4 months versus 14.9 months], a
longer disease-free survival and a 9% increase of the 5 year
overall survival (OS). [11]. In retrospective comparison with
chemoradiation trials, immunoradiation with cetuximab
showed similar control rates in terms of overall survival
(OS) and local control rate (LCR) [16]. Since the radio-
immunotherapy with cetuximab is a feasible treatment op-
tion that overall shows a low incidence of systemic side
effects and a favourable toxicity profile, it is especially in-
dicated for older patients and patients with comorbidities.
Recently updated EHNS-ESTRO-ESMO guidelines rec-
ommend radioimmunotherapy with cetuximab with a
level of evidence of II and a recommendation grade B [8].
Skin reactions are known to be the most frequent side
effect of EGFR inhibitor therapy. About 90% of patients
treated with cetuximab develop an acneiform rash, but
only 15% of patients develop a grade 3 or 4 skin rash
[17-20]. Besides, patients on cetuximab treatment might
develop other skin reactions like a xerosis cutis followed
by a severe pruritus, hair and nail alterations, a stomatitis
and eye abnormalities. All of those skin reactions can
result in non-compliance as well as in an interruption or
even discontinuation of an effective antitumor treatment
approach. Besides, patients often feel anxious related to
the cosmetic appearance of the rash and have the feeling
to be stigmatized which can lead to psychosocial side
effects and can negatively affect patient quality of life [21].
The most frequently seen side effect of radiotherapy in
patients with head and neck cancer is radiation dermatitis
that occurs in approximately 90% of patients. If cetuximab
is administered simultaneously, an overlap of radiation
and cetuximab induced skin reactions is seen in the radi-
ation field which may lead to very severe skin toxicity
[22,23]. An retrospective evaluation of acute toxicity of
skin and mucosa in patients with head and neck cancer
receiving radiotherapy (RT) alone or in combination with
radiotherapy plus chemotherapy (RCT) or with cetuximab
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grade 3 overall skin toxicity in 27.6% of the RIT patients
compared to 0% in patients only receiving RT and com-
pared to 7% in patients receiving RCT [22]. Cetuximab
associated acneiform rash grade 3 was observed in 7% of
the RIT patients. In this publication cetuximab did not
lead to a higher rate of RT interruptions compared to RT
and RCT. Eight weeks after RT all patients had recovered
from these dermatological side effects [22]. Bonner et al.
reported on 21% of patients with grade 3/4 radiation
dermatitis in the RT group. In the radioimmunotherapy
group, however, a significant increase to 35% of grade 3/4
radiation dermatitis was observed. Since there is a discus-
sion about a possible correlation between the intensity of
acneiform rash and the efficacy of therapy [11], Bonner
et al. conducted a subgroup analysis showing an overall
survival benefit in patients developing an acneiform rash
grade 2–4 compared to patients with acneiform rash grade
0–1. Such patients survived for a median of 69 months,
whereas patients who had no reaction or only a mild rash
had a median survival of 26 months [11]. Thus, it might
be possible that the acneiform rash is a predictive bio-
marker for immunological response and, furthermore, that
it is conductive for optimal outcome. A similar pattern
has already been shown for other types of cancer [24-26].
Vermorken and colleagues,, however, conducted a thor-
ough analysis of cetuximab-induced skin reactions and
acne-like rash with clinical markers of activity. Although
development of skin reactions and acne-like rash appeared
to trend toward improved response and disease control,
early development of these toxicities was not associated
with improved response or overall survival [27].
Budach et al. reported on two patients who had severe
radiation dermatitis while receiving radioimmunotherapy
with cetuximab [23]. Severe radiation dermatitis may
occur after irradiation alone, but grade 4 lesions are
rarely observed. Coexisting conditions like previously
received chemotherapy or radiotherapy or even intensive
sun exposure in the past may predispose for aggravation
of radiation and cetuximab induced skin reaktions. Liver
or renal dysfunction with possible alterations of pharma-
codynamics of cetuximab may also predispose patients
to develop more severe radiation dermatitis [28]. In a
retrospective survey in EORTC institutes, the members
observed that in 49% of patients treated with cetuximab
and concurrent radiotherapy developed grade 3 or 4
radiation dermatitis [29]. Hence, the incidence of these
severe skin reactions was twice as high compared to that
reported by Bonner et al. [11,12]. The real percentages
of grade 3 and 4 radiation dermatitis during combined
radioimmunotherapy with cetuximab, however, have
never been evaluated. Furthermore, the differentiation
between radiation dermatitis and cetuximab induced
acneiform rash seems to be important for therapeuticand prognostic reasons but has never been explored in
detail so far. Thus, a prospective, multicenter large-scaled
study is warranted to distinguish radiation dermatitis from
cetuximab induced skin reactions, to determine the real
incidence of the different types of skin reactions in a large
cohort of patients, and, besides, to identify and evaluate
biomarkers and surrogates correlating with clinical efficacy
and outcome.
The HICARE trial is a prospective, open phase IV trial
exploring the prominent side effects of skin toxicities of
combined radioimmun(chemo)therapy with the EGFR in-
hibitor cetuximab (Erbitux®) in patients with LASCCHN
in great detail. The HICARE study is a national multicen-
ter trial in Germany, 40 centers will participate.
Methods/design
Study design
The HICARE study is designed as an open-label, prospect-
ive, multicenter, one-armed phase IV study according to
the German drug law evaluating the incidence and severity
of radiation dermatitis and acneiform rash in patients with
locally advanced head and neck cancer treated with com-
bined radioimmuno(chemo)therapy with cetuximab.
Study objectives
Primary endpoint of the study is the rate of radiation
dermatitis grade 3 and 4 according to the National
Cancer Institute, Common Terminology Criteria for Ad-
verse Events (NCI CTCAE), version 4.02. Secondary end-
points are skin related parameters like the rate of radiation
dermatitis grade 1 and 2, the rate of cetuximab-induced
acneiform rash grade 1–4, the rate of cetuximab-induced
rhagades (all grades), the rate of cetuximab-mediated
nail changes (all grades). Furthermore secondary endpoints
include parameters of efficacy, i.e. objective response rate
(ORR), locoregional control rate (LCR), progression free
survival (PFS), overall survival (OS), safety parameters, i.e.
the median dose density of radiation and the safety profile
of the applied radiation protocol as well as quality of
life (QoL). In addition, feasibility aspects of the treatment
schedule in common routine practice and applied to pa-
tients presenting an increased comorbidity rate compared
to the study population studied in the pivotal phase III trial
will be evaluated. For translational research genomic ana-
lyses of peripheral blood samples are carried out at several
time points during the trial. The results of the translational
research will be correlated with safety parameters, clinical
outcome and quality of life.
Trial organization
The HICARE study was designed by the study initiators
at the Department of Radiation Oncology of the University
of Heidelberg. It is an investigator initiated trial (IIT).
The trial is conducted as multicenter trial and 40 centers
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cetuximab is commercially available and it will be admin-
istrated in combination with radiotherapy as recom-
mended by the SmPC [30}.
Coordination
The overall coordination is performed by the Department
of Radiation Oncology of the University of Heidelberg.
The Department of Radiation Oncology of the University
of Heidelberg is responsible for overall trial management,
trial registration, database management, quality assurance
and reporting. Biometrical data analyses are conducted by
the CRO iOMEDICO.
Investigators
The investigators are experienced oncologists, i.e.
radiooncologists and medical oncologists, specialized in
treating patients with locally advanced head and neck
cancer. Patients will be recruited and treated by the in-
vestigators of the 40 participating sites in Germany (see
acknowledgement).
Quality assurance
According to the guidelines of Good Clinical Practice
(GCP) and other applicable guidelines and regulations
the site monitoring will be performed by an independent
monitor.
Ethics, informed consent and safety
The final protocol was approved by the leading ethics
committee of the Medical Faculty of the University of
Heidelberg (AFmu-387/2010), the local ethics committee
of every participating center and the Paul-Ehrlich-Institute.
The HICARE trial is registered at the European Clinical
Trials Database (EudraCT-No. 2010-019748-38) and
at www.clinicaltrials.gov, number NCT01553032. The
HICARE study complies with the Declaration of
Helsinki in its recent German version, the Medical As-
sociation’s professional code of conduct, the principles of
Good Clinical Practice (GCP) guidelines and the Federal
Data Protection Act. The trial will also be carried out ad-
hering to local legal and regulatory requirements.
For each patient recruited into the study, written in-
formed consent is essential prior to inclusion into the
study after extensive information about the intent of the
study, the study regimen, potential associated risks and
side effects as well as potential alternative therapies. The
investigator will not undertake any diagnostic measures
specifically required for the clinical trial until valid
consent has been obtained.
Patient selection
A total of 500 patients with locally advanced (UICC stage
III, IVA or IVB), non-metastatic, squamous cell carcinomalocated in the oral cavity, oropharynx, hypopharynx, or
larynx with measurable disease will be included. For par-
ticipation in the trial lymph node involvement is allowed,
but a spread of the tumor to other parts of the body is an
exclusion criterion. Each patient will receive the combined
radioimmunotherapy as described above, i.e. radiation
therapy (IMRT or 3D-radiation) and cetuximab.
Inclusion criteria include:
 Signed written informed consent
 Age ≥ 18 years of age
 Eastern Cooperative Oncology Group performance
status (ECOG) of 0 to 2
 Life expectancy > 6 months
 Histologically confirmed locally advanced (stage III
or IVA, IVB), non-metastatic squamous cell
carcinoma of the oral cavity, oropharynx,
hypopharynx and larynx (T2-4, Nx, M0).
 Adequate bone marrow, liver and renal function
according to SmPC of cetuximab based on
laboratory assessments raised within 7 days prior to
start of study treatment.
 Women of childbearing potential must have had a
negative serum or urine beta-HCG pregnancy test
within 7 days prior to the first administration of
study treatment or must have a documented
condition that prohibits pregnancy (e.g. post-
menopausal; hysterectomy).
 Commitment to use of adequate contraception:
patients enrolled in this trial must be willing to use
effective birth control measures during the course of
the trial and the subsequent 2 months
Exclusion criteria include:




 Prior exposure to EGFR pathway targeting therapy
 Surgery within the last 30 days
 Known allergic/hypersensitivity reaction to any drug
scheduled for the study treatment
 Previous or concurrent cancer within 5 years prior
to study entry that is distinct in primary site or
histology except adequately treated basal cell
carcinoma or preinvasive cervical carcinoma.
 Substance abuse, medical, psychological or social
conditions that may interfere with the patient’s
participation in the study or evaluation of the study
results as judged by the investigator
 Any condition that is unstable or could jeopardise
the safety of the patient and their compliance in the
study as judged by the investigator
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 Pregnant or breast-feeding women
Work-up
Routine staging includes physical examination, chest X-
ray, head and neck panendoscopy under anaesthesia, and
head and neck computed tomography (CT) scan or mag-
netic resonance imaging (MRI) and abdominal ultrasound.
All patients will be evaluated for head and neck surgery.
In case resection is either surgically or medically impos-
sible or the patient refuses to undergo the procedure,
standard chemoradiation with carboplatin and 5-FU
(without cetuximab) will be chosen according to current
guidelines. In case that primary chemoradiation is medic-
ally impossible due to comorbidities, reduced general con-
dition, in- and exclusion criteria for radioimmunotherapy
will be evaluated and patients will be checked for eligibility
for the HICARE trial. It is to note that a combination of
the applied radioimmunotherapy with a chemotherapy in
terms of a combined radioimmunochemotherapy (e.g.
with cisplatin or carboplatin/5-FU) is not an exclusion
criteria and, if applied, will be evaluated separately.
Patients previously treated with induction chemotherapy
are allowed to participate in this trial. Should a patient be
eligible, information about participation in the study in-
cluding potential risks and benefits is given to the patient.
As soon as written consent is obtained, patients can be
included into the trial and the required documentation
will be provided by the study center (Clinical Trial Center,
Department of Radiooncology, University of Heidelberg
Medical Center).
After inclusion, for planning of the radiotherapy each
patient receives a CT-scan in an individually adjusted
precision immobilization device.
If a patient refuses treatment within the HICARE trial,
the same standard combined radioimmunotherapy will
be offered if chemoradiation is not applicable.
Investigational drug according to German drug law
Cetuximab (Erbitux®)
The commercial available monoclonal antibody cetuximab
will be applied according to the German SmPC [30].Table 1 Possible radiotherapy protocols for treatment of pati
modification for IMRT
Regime Total dose Single dose (once a day) Sing





Twice a day 72-76,8 Gy in
60–64 fractions
- - 1,2 G
Concomitant
boost
72 Gy in 42
fractions
32,4 Gy; 1,8 Gy/fraction; 5 fractions/
week duration: 3,6 weeks
a.m.:
18 G
(helical) IMRT 66 Gy in 30
fractions
Intergrated Boost 5 fractions /week
duration: 6 weeks
- -Cetuximab is given with a loading dose of 400 mg/m2 of
body surface as an intravenous infusion on day 1. Subse-
quently, the regular weekly dose during the radiotherapy
is 250 mg/m2 of body surface on days 8, 15, 22, 29, 36 and
43. A prophylactic premedication with corticosteroids and
antihistamines is required to reduce the incidence of
infusion-related reactions such as allergic or hypersensi-
tivity reactions.
Radiation therapy
Irradiation is applied as modern standard radiotherapy
for LASCCHN, i.e. intensity modulated radiation therapy
(IMRT) or 3D-conformalradiotherapy. Within the HICARE
trial, the standard radiotherapy scheme of the institution
can be applied. A summary of radiation protocols routinely
used for this indication is given in Table 1. Radiation
therapy can be carried out on an outpatient basis unless
the patient’s condition requires hospital admission.
Supportive therapy
Antihistamines such as clemastine or dimentinden and
steroids are administered intravenously prior to the ap-
plication of cetuximab according to the SMPC [30]. Skin
reactions, especially acneiform rash and xerosis cutis, are
treated according to current treatment recommendations.
Whenever it is necessary, metoclopramide or 5-HT3-
antagonists are used for antiemetic treatment.
Radiation induced skin reactions are treated with mild
moisturizing lotion according to in-house protocols.
Translational research
HPV
Patients will not be selected by human papillomavirus
(HPV) status, but since HPV is increasingly being found
in head and neck cancers and since there is a prognostic
importance of the HPV status [2,31-33], tumor samples
will be tested for HPV status. It remains to be seen if the
particular subgroup of patients with HPV-positive tumors
is the one in the HICARE trial that may benefit more from
the addition of cetuximab and may have better outcomes
than those with HPV-negative tumors.ents with LASCCHN according to Bonner et al. (12), plus
le dose (twice a day)
y/fraction; 10 fractions/week Duration: 6–6,5 weeks
21,6 Gy; 1,8 Gy/fraction; 5 fractions/week Duration: 2,4 weeks p.m.:
y; 1,5 Gy/fraction; 5 fractions/week Duration: 2,4 weeks
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For the translational research program, genomic DNA
and Total-RNA (including micro RNAs) of peripheral
blood samples will be collected from each subject prior to
the first administration of cetuximab (day 1), additionally
during the treatment on day 8 (prior to the second admin-
istration of cetuximab) and on day 22 (prior to the fourth
administration of cetuximab). The goal of these studies is
to identify molecular predictors of normal tissue and
tumor response to combined radioimmunotherapy using
transcriptomics, microRNA or epigenomic approaches.
Assessment of skin reactions
Skin-related toxicities like cetuximab-induced acneiform
skin rash and radiation dermatitis will be graduated by a
physician in every participating center. Each week just
before the cetuximab application a photo series will be
taken to get an objective measure for grading skin toxic-
ities. Photos will be taken with the same type of camera.
These photos will be blinded and separately reevaluated
by experienced physicians authorized by the sponsor, i.e. a
radiooncologist, a medical oncologist and a dermatologist.
Based on the photo documentation it will be possible to
define the correct graduation of the acute skin toxicities
and, besides, to compare them with historical data from
the Bonner trial [11,12] if using NCI CTCAE v. 4.2 and
the former version 3.0 to receive this comparability with
the pivotal trial [34,35].
Quality of life assessment
Assessment of quality of life is one of the secondary
objectives of the trial. The following questionnaires will
be used: EORTC QLQ-C30, the head and neck cancer-
specific module EORTC QLQ H&C as well as the
Dermatology Life Quality Index (DLQI). The EORTC
QLQ30 is a general measure of quality of life in cancer
patients, whereas the DLQI is a specific measures 10-
question validated questionnaire which is frequently
been used in dermatology. These assessments will be
performed at the baseline visit, on day 22 during the
course of the treatment, within the last week of radio-
therapy and at the first follow-up visit.
Safety and discontinuation of treatment
Radiotherapy-related toxicities will be assessed using the
NCI Common Toxicity Criteria (CTCAE v.4.2) and the
outdated version 3.0 in order to achieve a comparison to
former studies, furthermore by duration, onset, and rela-
tionship to study treatment [34,35]. Toxicity will be eval-
uated at baseline, weekly during radiation therapy (blood
count, electrolytes, chemistry, clinical examination, pa-
tient visits) and at follow-up visits. Unacceptable toxicity
is defined as unpredictable or irreversible grade 4
toxicity. Expectable possible acute radiation-inducedtoxicities (up to 3 months after irradiation) comprise
skin toxicity (desquamation, epitheliolysis, edema, bleed-
ing, necrosis, erythema, hyperpigmentation, rash, pruritus),
nausea, vomiting, fatigue, weight loss, loss of appetite,
pneumonitis, haematological toxicity including leukopenia,
thrombocytopenia or anaemia. Adequately treated these
symptoms could be resolved within two to three weeks.
However, transient parenteral nutrition therapy and hydra-
tion might be necessary in some patients. All acute
radiation-induced toxicities should completely resolve
within a few weeks post radiation therapy.
Cetuximab-induced adverse events are treated according
to SmPC and according to current treatment recommen-
dations [21]. Importantly, according to SmPC cetuximab
should be delayed for up to two subsequent infusions in
patients facing a grade 3 acneiform rash. Cetuximab can
be restarted after resolution of the rash to grade 2 or
less. Cetuximab needs to be delayed on a second or
third occurrence of a grade 3 skin reaction for up to two
consecutive cycles and dose reduction to 200 mg/m2 or
150 mg/m2, respectively, will be needed. Any further oc-
currence of grade 3 acneiform rash will lead to discon-
tinuation of cetuximab treatment according to the
recommendations of the SmPC.
Adverse events
Patients’ toxicities are to be classified and documented
according to the NCI Common Toxicity Criteria v. 4.2.
Toxicity is documented weekly during RIT and prior to
each application of cetuximab as well as at the follow-up
visit. The investigators will report all Serious adverse
events (SAE) immediately to the sponsor or his legal
representative. Serious adverse events (SAE) are any
untoward medical condition that occur and result in
death, are life-threatening, require hospitalization or
prolongation of existing inpatient’s hospitalization, result
in persisting or significant disability or incapability, or
are a congenital abnormality of birth defect. For all SAE,
the documents and patient data must be verified by the
responsible study personnel.
Statistical considerations
The primary objective is the rate of radiation dermatitis
CTC AE grade 3 and 4 and will be calculated based on
the individual events as reported by the investigators.
Bonner et al. [12] reported an incidence of radiation
dermatitis of 18% for patients treated with radiotherapy
alone compared to 23% for patients treated with radio-
therapy and cetuximab. Based on data of this pivotal
trial, 500 patients (with a drop-out rate of 5%) will be
needed to show the 95% confidence interval to stay
within the limits of 4% uncertainty (binomial test). The
sample size is also sufficient to analyse the secondary
objectives. The statistical analysis will be carried out
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GmbH) and R (www.r-project.org). Descriptive analyses
will be done of all documented data. To compare the
study population of the HICARE trial with the data of
the pivotal trial by Bonner et al. [11,12], descriptive
statistical methods without formal testing will be used.
The analysis of the primary objective and further safety
parameters will be done with all patients who received
at least 1 dose of study medication cetuximab and at
least 1 fraction of RT. Analyses of efficacy parameters
will be done by the intention to treat population. Details
on the evaluation can be found in the statistical analysis
plan prepared for the study and which will be finalized
and authorized by the study biostatistician and the prin-
cipal investigator prior to performing any analysis.
Objective response evaluation
Objective response will be evaluated according to RECIST
criteria v.1.01 [36].
Discussion
For patients with LASCCHN, cetuximab plus radiotherapy
significantly improves overall survival at 5 years compared
with radiotherapy alone, confirming cetuximab plus radio-
therapy as an important treatment option in this group of
patients [11,12]. However, there are no data available about
a formal comparison between the combination of radio-
therapy with cisplatin or cetuximab. The current guidelines
still recommend using standard radiochemotherapy in pa-
tients with LASCCHN fit enough to undergo chemother-
apy because there is no randomized, prospective trial
comparing radiochemotherapy versus immunoradiotherapy
in this patient group [8,37]. Chemoradiation is known to be
associated with significant toxicities and, furthermore, its
efficacy is questioned in the elderly population. The magni-
tude in effect of the radioimmunotherapy with cetuximab,
however, is similar or even better than that achieved by
chemoradiation and it proved to be less toxic [8,11]. The
control rates were the same in retrospective comparison
with radiochemotherapy trials [16].
For better patient selection, i.e. for definition of a
patient cohort that benefits more from the less intense
and less toxic radioimmunotherapy regimen and a pa-
tient cohort that benefits more from the more intense
chemoradiation-based approach, patient characteristics
including clinical and molecular prognostic markers and
predictive surrogates have to be defined. Several clinical
characteristics of patients with HNSCC have been linked
to favourable prognosis, including non-smoker, mini-
mum exposure to alcohol, good performance status, and
absence of co-morbid disorders [38]. Several studies
have shown a correlation between genetic aberrations, i.e.
a p53 mutation, and lower response rates to chemotherapy
and shorter overall survival times [39-42]. The HPV-statusis associated with outcome, too [2]. To date in LASCCHN
specific genetic alterations, however, are not known [43].
Testing for genetic and proteomic alterations in a large
patient cohort may define prognostic and predictive
biomarkers that help to identify patients who are at great
risk for progression or treatment resistance and patients
who might benefit most from radioimmunotherapy.
Skin reactions, the most common side effect of radio-
therapy and also of anti-EGFR-treatment strategies like
cetuximab, have not been evaluated and characterized in
detail. Interestingly, almost all studies addressing EGFR-
inhibitor-induced skin rash done in patients with meta-
static colorectal cancer suggest that its severity is a suitable
surrogate marker for efficacy of anti-EGFR therapy [44-47].
In patients with LASCCHN, the pivotal trial by Bonner
et al. also showed that cetuximab-treated patients with
prominent cetuximab-induced acneiform rash grade 2 or
above had a better overall survival than patients with no
or grade 1 rash [11]. A retrospective exploration of several
trials done with panitumumab, another anti-EGFR mono-
clonal antibody, confirmed an association between clinic-
ally graded skin toxicity and patient-reported outcome,
quality of life, longer progression-free survival and overall
survival [26]. Other trials in patients with metastatic colo-
rectal cancer and other solid tumors did not show any
correlation between skin rash and efficacy of anti-EGFR
therapy [48].
Thus, a clinical trial is warranted in patients with
LASCCHN to evaluate the efficacy and toxicity of the
radioimmunotherapy with cetuximab in a large patient
cohort and to focus on biomarker research to better se-
lect patients who might benefit better from this treat-
ment approach than others.
The HICARE study will be one of the largest clinical
trials ever being performed in patients with LASCCHN.
It will help to better understand the different clinical
characteristics of skin reactions induced by radiotherapy
and by cetuximab treatment, to identify molecular pre-
dictors and surrogates for treatment response and resist-
ance and to better define a patient population where a
less toxic regimen like the radioimmunotherapy with
cetuximab would constitute the primary treatment op-
tion and other patient populations where a more intense
chemoradiation-based approach is needed.
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